



YungShin Global Holding Corporation Investor Conference

**Provide the best products
to improve human health**

Sep. 21, 2026



www.yungshingroup.com



Disclaimers

This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (<http://mops.twse.com.tw/mops/web/index>)





Table of Contents




- **YungShin Group Overview**
- **Operational Results for first half year 2026**
- **Business Strategy**





Introduction of YungShin Group

A pharmaceutical Group have been established over 60 years, looking forward being a-century enterprise.





Listing History

Three subsidiaries list in TW, CN and MY.

- 1993- Listing of Yungshin Pharmaceutical, Taiwan



臺灣證券交易所

- 2000-Listing of Yung Zip Chemical, Taiwan



證券櫃檯買賣中心
Taipei Exchange

- 2004-Listing of Y.S.P. Southeast Asia Holding, Malaysia



- 2011-Listing of YungShin Global Holding, Taiwan



臺灣證券交易所

- 2025-Listing of Vetnostrum, Taiwan



臺灣證券交易所



www.yungshingroup.com



R&D and Production Planning Worldwide

Night manufacturing and operating bases cross US, CN, JP and South Asia.





YungShin Group Main Production Bases(1/2)

Subsidiaries in TW and US have been certified by USFDA.

Production bases of YSG have covered 5 continents and products sold over 35 countries.



1990
Yung Zip
(Taiwan)



1998
Carlsbad
(USA)



2004
YungShin
(Taiwan)





YungShin Group Main Production Bases(2/2)

MY, VN and IN sites have exported to Southeast Asia, middle East, North Africa and Oceania.



(Malaysia)



(Vietnam)



(Indonesia)



(Malaysia)



NATIONAL
PHARMACEUTICAL
REGULATORY
AGENCY



Health
Canada

Santé
Canada



Australian Government

Department of Health

Therapeutic Goods Administration



衛生福利部
食品藥物管理署
Taiwan Food and Drug Administration



TGA Health Safety
Regulation




www.yungshingroup.com



YSH Stable Business

Stable payout dividend in every economy cycle

NT/Share





Operational Results for first half year of 2026

**Provide the best products
to improve human health**





YSH Consolidated Statements of Income

Operating revenue decreased by 12.40% and
Income from operations decreased by 23.31% for first half year of
2026 and 2025.
(Expressed in millions of NTD)

	2026 H1	2025 H1	Growth rate
Operating revenue	3,771	4,305	-12.40
Operating costs	(2,096)	(2,402)	-12.74
Gross profit	1,675	1,903	-11.98
Operating expenses	(1,096)	(1,148)	-4.53
Income from operations	579	755	-23.31
Non-operating income & Expenses	47	(108)	-143.52
Profit before income tax	626	647	-3.25
Profit for the period	472	452	4.42
Earnings per share	1.63	1.57	3.82



YSH Consolidated balance sheet (1/2)

Comparing total assets increased by 5.54% in 2026 and 2025.

(Expressed in millions of NTD)

	2026H1	%	2025H1	%
Cash and cash equivalents	1,681	13	1,893	15
Inventories	2,772	21	2,770	22
Accounts receivable	1,588	12	1,644	13
Other current assets	1,527	12	921	8
Property, plant and equipment	3,826	29	3,565	29
Other non-current assets	1,782	13	1,691	13
Total assets	13,176	100	12,484	100



YSH Consolidated balance sheet (2/2)

Comparing total shareholder's equity increased by 3.11% in 2026 and 2025.

(Expressed in millions of NTD)

	2026H1	%	2025H1	%
Short-term borrowings	413	3	330	3
Other current liabilities	2,610	20	2,495	21
Long-term borrowings	848	7	567	5
Non-current liabilities	721	5	767	5
Total shareholder's equity	8,584	65	8,325	66
Total liabilities and equity	13,176	100	12,484	100



YSH Consolidated Operating Revenue by area

Comparing consolidated revenue decreased by 12.40% for first half year of 2026 and 2025.

(Expressed in thousands of local currency)

	Currency	2026	2025	Growth rate
		H1	H1	
Taiwan	TWD	2,834,511	3,452,438	-17.90
USA	USD	12,280	9,726	26.26
China	RMB	12,805	10,342	23.82
Japan	JPY	2,445,535	2,313,290	5.72

1. The list the revenues of companies that YSH holding only more than 50% shares.
2. Operating revenue by area is based on financial report, and the growth rate is calculated in local currency.





Business Strategy


**Provide the best products
to improve human health**





Operating Strategy of YSH

Eight aspects to accomplish steady investment and pragmatic operation for creating the best interests of shareholders.





Business Strategy of YSH

Internal investment management and external M&A for strengthening group efficiency

The strategy will balance short, medium and long term group development and shareholders' equity



Internal investment management

•Production

Cross company platform communication and production experience optimization

•Marketing

Search, supply, marketing promotion transnationally

•Personnel(ESG)

Integrate experiences communication of joint factory inspection for national laws and regulations

•R&D

Project coordination, R&D technology transfer reducing investment

•Finance

Supervising by YSH, apply endorsement and guarantee to reduce financial burden and increase investment efficiency



External M&A



•New business

1. Try to get into Medical Device
2. Multi-angle consideration relating to health industry

•New market

1. Expand product to Excises
2. New market evaluation such as in Southern US.

•New product/technology

1. TW/MY new injectable site.
2. Obtain manufacturing technology from GlyTech Inc.
3. Evaluating biological medicine, cell therapy and other fields.





Group IP Investment R&D and Drug License Status

項目	2023	2024	2025
Total R&D (K, NT)	329,818	387,454	392,407
Ratio of Sales(%)	4.69%	4.82%	4.68%

Prescription Drug License Number





CarlsbadTech (YungShin US)

Total solution from production to marketing as window for Asia company to enter US market.



History:

Company started in 1990 and facility operated in 1998.

Location:

Located 30 miles north of San Diego, 130 miles south of LAX, 90 miles from Port of Los Angeles.



Production



Laboratory

Space:

cGMP compliance solid dosage form manufacturing facility (Approx. 21,000 sq.ft.).

Production Capability:

About 800mio to 1,000mio tabs capacity per year.

Customer:

Cover US 96% customers in sales channel with 50 stats selling permit.



**OWN BRAND · CMO ·
CDMO · PACKING · RA
US market total solution**





Maximize Value Chain Based on Product

Strengthen the competitiveness of the group through vertical integration and horizontal expansion



Maximize Value Chain

Vertical integration : Maximize Production Value Chain

- Vertical integration of main products through manufacturing and marketing of intermediate, API and FDF.
- Master raw material intermediate suppliers through investment and contract manufacture.
- Local production reduce the risk of trade barriers.
- Sharing R&D resource from in Taiwan and Malaysia lab.
- Continually strengthen product line competitiveness (integrate value chain and expand production batch size)

Horizontal expansion : Maximize Sales Value Chain

- Future product lines drive from market orientation
- Deep development of digestive tract, pain, hypersensitivity and anticancer fields.
- Increasing investment benefit through Integration product lines in various countries, mutual distribution, technology transfer, and development together.
- Expansion of four major business: API, FDF, OTC and animal drugs



YungShin group CDMO


Business cover from API, Originator, Brand, Food supplement and Vet Drug





Diversified Business Map

Expansion and exposure new business based on core health care relative business





Core Value of YungShin Group

Provide the best products to improve human health from Taiwan



Spirit of YungShin Group :

We produce medicine that we would give it to our own families.

We establish Nursing Home that our elders would love to go to.

Social welfare covered by cooperate social responsibility



Q&A

**Provide the best products
to improve human health**

